Regulatory decisions
Approvals and other regulatory decisions, in the order we post them.
November 2026
- FDAApprovedDurvalumab with enfortumab vedotin-ejfvGenitourinary
Durvalumab (Imfinzi) + enfortumab vedotin-ejfv approved by the US FDA for muscle-invasive bladder cancer (MIBC)
Genitourinary. November 15, 2026.
October 2026
- FDAApprovedTalazoparib + enzalutamideGenitourinary
FDA approves talazoparib plus enzalutamide in prostate cancer with HRR gene mutations
Genitourinary. FDA. October 26, 2026.
- FDAAccelerated approvalDostarlimabGastrointestinal
FDA NEWS | AZUR 1 Update in Rectal Cancer
Gastrointestinal. FDA. October 19, 2026.
- FDAApprovedAtezolizumab with fluoropyrimidine + oxaliplatinGastrointestinal
Atezolizumab approved with fluoropyrimidine + oxaliplatin for adjuvant Stage III dMMR Colon Cancer (adults & peds ≥2 yrs).
Gastrointestinal. FDA. October 12, 2026.
- FDAApprovedTucatinib + trastuzumab + pertuzumabBreast
FDA NEWS: HER2CLIMB-05 Update
Breast. FDA. October 7, 2026.
The week in oncology, in your inbox
The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.



